Wolfe Research Initiates Thermo Fisher Coverage with Outperform Rating

Wolfe Research analyst Mike Polark initiated coverage of Thermo Fisher Scientific Inc. (NYSE: TMO) with an Outperform rating and set a price target of $535, according to a report from TheFly on June 1, 2026.

Rating Change

Prior to this coverage, Wolfe Research had no official rating for TMO. The new rating is Outperform with a $535 price target, indicating expected upside from current levels.

Analyst Rationale

Polark believes Thermo Fisher holds a strong position in the life sciences tools sector, especially with growing demand for weight loss drug development solutions. Its diversified product and service portfolio provides a competitive edge.

Context

This coverage comes amid increased interest in life sciences tools stocks due to demand for diabetes and obesity drugs. Other analysts have mixed views; some see the stock as undervalued, while others caution about high valuations.

What to Make of It

The initiation of positive coverage by Wolfe Research boosts investor confidence in TMO, but it does not guarantee future performance. Investors are advised to monitor the company's quarterly results and sector developments.